Developer docs
API playgroundTry for free, no card

Search company profiles

Phebra

Full company profile

uuid000jasg

Namestring
Phebra
Legal namestring
Phebra Pty Ltd
Websiteurl
phebra.com
Company typeenum
Private
Founded yearint
1993
Descriptiontext

Phebra is an Australian-owned pharmaceutical manufacturer founded in 1993 (originally as Pharmalab, renamed Phebra in 2007) that develops, manufactures, and supplies sterile injectable critical care medicines for hospitals and healthcare professionals. Its portfolio spans more than 60 medicines across therapeutic areas including antidotes (Acetadote, DigiFab), cardiovascular drugs (Rapiblyk, Brevibloc, Narcan), oncology products (Phenasen/Arsenic Trioxide), pain management (Caldolor, Laceraine, Morphine Oral Solution), emergency and obstetric medicines, and diagnostic agents. Manufacturing is conducted at a TGA-licensed, GMP-compliant, FDA-accredited multi-purpose sterile injectables plant at Lane Cove West, Sydney, equipped with a robotic aseptic syringe and vial line; the facility was expanded in 2019 ($4M, +3,000m²) and again in 2020, with further capacity investment committed through 2026. Manufacturing licenses have been progressively broadened, in 2022 to include clinical trials therapeutic goods and in 2025 to include prescription oral and dermatological solutions.

The business operates through three revenue streams: direct product sales via the PhebWeb online ordering system and Therapeutic Specialist Representatives in Australia; licensing and distribution agreements with international partners (e.g., Flexipharm Austrading for the UK, Healthcare Logistics for NZ); and contract development and manufacturing services for other pharmaceutical companies. Customer segments are hospitals and healthcare professionals (primary), plus pharmaceutical companies seeking Asia-Pacific commercialization partners. Pricing is tiered across healthcare providers, licensed wholesalers, and credit accounts requiring minimum $10,000/quarter spend over three consecutive quarters. The group has established wholly-owned subsidiaries in the UK (2018), Canada (2019), New Zealand, and Singapore, holds a minority equity stake in Flexipharm Austrading (2021), and in 2024 launched subsidiary Phero Pharma to address Australian medicine shortages through in-licensing and alternative global sourcing.

Phebra's strategic posture is anchored in regulatory moats (TGA, FDA, GMP), a niche critical-medicines portfolio where supply security matters to hospitals, and incremental geographic and dosage-form expansion. Recent moves include pipeline expansion (Rapiblyk in March 2026, Anaesthetic Wound Gel in April 2026, Sterile Theatre Packs in 2023), a co-development partnership with the University of Wollongong for leukemia and pancreatic cancer drug development (2023), and a licensing deal with Medsenic for oral arsenic trioxide (2021). The company remains privately held with no disclosed funding rounds or revenue figures, and headcount is described as 'more than 130 people' against a stated 51-100 band.

Short descriptiontext

Phebra is an Australian pharmaceutical manufacturer founded in 1993 that develops, manufactures, and supplies sterile injectable critical care medicines to hospitals and healthcare professionals, operating TGA-licensed and FDA-accredited facilities in Sydney with subsidiaries across the UK, Canada, New Zealand, and Singapore.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLane Cove, Australia
HQ citystring
Lane Cove
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectable pharmaceuticals, critical care medicines, pharmaceutical contract manufacturing, specialty hospital pharmaceuticals, clinical trial drug manufacturing
Industry1 code
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Sterile Injectable Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Direct sales of manufactured sterile injectable pharmaceuticals to healthcare providers, hospitals, and wholesalers through PhebWeb online ordering system and field sales representatives. Products sold include over 60 medicines across therapeutic areas.

phebra.com
2License and Distribution Agreements
TypeLicensing Royalties
Description

License and distribution agreements with international partners such as Flexipharm Austrading for UK market access. Phebra out-licenses products globally across Pacific region, Asia, Europe, Canada, South Americas and Middle East.

prnewswire.com
3Contract Manufacturing
TypeProfessional Services
Description

Contract development and manufacturing services for other pharmaceutical companies on a fee-for-service basis

phebra.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details3 tiers
1Healthcare Provider Orders
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Orders under $400 incur $50 dispatch and handling charge (exclusive of GST). Products priced per unit with list price current at date of order.

phebra.com
2Licensed Wholesaler Orders
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Orders under $1,500 incur $100 dispatch and handling charge (exclusive of GST).

phebra.com
3Credit Account Customers
ModelSubscriptionBilling cadenceMonthly
Notes

Credit accounts available for customers purchasing minimum $10,000 (excl GST) per quarter over 3 consecutive quarters. Payment due 30 days from invoice date.

phebra.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Phero Pharma
Description

Subsidiary company established to help fulfill medicine shortages in the Australian health system via sourcing alternative products in the global market and in-licensing.

phebra.com
Core offering1 text field

Phebra develops, manufactures, and supplies high-quality sterile injectable pharmaceuticals and critical medicines for serious and life-threatening conditions. Operating from a TGA-licensed, GMP-compliant and FDA-accredited facility in Lane Cove West, Sydney, it produces over 60 medicines across therapeutic categories including antidotes, cardiovascular, oncology, pain management, anaesthesia, neonatal care, and diagnostics, and is licensed to manufacture therapeutic goods for clinical trials. The company also provides contract development and manufacturing services and licenses its products globally through distribution partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 328 tonnes carbon saved per year through energy efficiency initiatives
+1 more record
Product overview1 text field

Phebra is an Australian pharmaceutical company that develops, manufactures, and supplies high-quality sterile injectable pharmaceuticals and critical medicines. The core product portfolio includes over 60 medicines across therapeutic areas: antidotes (Acetadote, DigiFab), cardiovascular drugs (Rapiblyk, Brevibloc, Narcan), oncology products (Phenasen/Arsenic Trioxide), pain management (Caldolor, Laceraine Gel, Morphine Oral Solution), emergency medicines, diagnostic agents (Charcotrace, Retinofluor), and infusion solutions. The company operates the PhebWeb online ordering system for customer direct ordering. In March 2024, Phebra established subsidiary Phero Pharma to address medicines shortages through alternative sourcing and in-licensing. Manufacturing is conducted at TGA-licensed facilities in Sydney, with distribution across Australia, New Zealand, Canada, UK, and Singapore.

Product and service17 records
1Acetadote (Acetylcysteine) Concentrated Injection
CategoryAntidote injectable
Description

Concentrated injectable antidote for paracetamol (acetaminophen) overdose used to protect the liver against hepatotoxicity in hospital and emergency settings.

2Phenasen (Arsenic Trioxide) Concentrated Solution for Infusion
CategoryOncology injectable
Description

Concentrated solution for infusion used for the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), including marketing approval for IV arsenic trioxide in Canada via Phebra Canada Inc.

3Rapiblyk (Landiolol Hydrochloride) Powder for Injection for Infusion
CategoryCardiovascular injectable
Description

Powder for injection for infusion providing rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter, and non-compensatory sinus tachycardia, supplied to Australian healthcare settings.

4Narcan (Naloxone Hydrochloride) Injection
CategoryEmergency antidote injectable
Description

Injectable opioid antagonist used for complete or partial reversal of opioid depression, including respiratory depression, in emergency and hospital settings.

5DigiFab (Digoxin-Specific Antibody Fragment) Powder for Injection
CategoryAntidote injectable
Description

Powder for injection used for the treatment of life-threatening or potentially life-threatening digoxin toxicity or overdose in hospital settings.

6Brevibloc (Esmolol Hydrochloride) Injection/Powder
CategoryCardiovascular injectable
Description

Short-acting beta-blocker injection/powder for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in hospital and perioperative settings.

7Caldolor (Ibuprofen) Concentrated Solution for Injection
CategoryPain and fever injectable
Description

Concentrated IV solution of ibuprofen for the management of acute postoperative pain and reduction of fever in adults requiring IV administration.

8Laceraine Topical Wound Anaesthetic Gel
CategoryTopical wound anaesthetic
Description

Topical lidocaine/adrenaline/tetracaine wound anaesthetic gel for wound closure and cleaning of painful minor wounds, supplied to healthcare professionals and hospital settings.

9Tadim (Colistimethate Sodium) Powder for Nebuliser Solution
CategoryInhaled anti-infective
Description

Powder for nebuliser solution indicated for treatment of lung colonisation and infections caused by Pseudomonas aeruginosa in cystic fibrosis patients.

10Cafnea (Caffeine Citrate) Injection/Oral Solution
CategoryNeonatal injectable/oral
Description

Caffeine citrate injection and oral solution for the short-term treatment of apnoea of prematurity in infants in neonatal hospital settings.

11Syntometrine (Ergometrine and Oxytocin) Injection
CategoryObstetric injectable
Description

Injection indicated for active management of the third stage of labour and the prevention and treatment of post-partum haemorrhage.

12Sterile Theatre Packs
CategoryAnaesthesia sterile presentation
Description

Ready-to-use sterile theatre packs, including bupivacaine and lidocaine with adrenaline presentations, supplied for surgical anaesthesia and analgesia in hospital operating theatre settings.

13Morphine Oral Solution
CategoryPain management oral solution
Description

Oral morphine solution for short-term management of severe pain when other treatment options have failed.

14Aramine (Metaraminol) Solution for Injection
CategoryEmergency cardiovascular injectable
Description

Solution for injection for prevention and treatment of acute hypotensive states occurring with spinal anaesthesia, and as adjunctive treatment of hypotension.

15Charcotrace (Activated Charcoal) Injection
CategoryDiagnostic injectable
Description

Activated charcoal injection used as a diagnostic agent for stereotactic localisation of impalpable breast lesions prior to surgical excision.

16Carbosorb X (Activated Charcoal) Suspension
CategoryOral antidote
Description

Oral activated charcoal suspension indicated for treatment of poisoning and drug overdosage by oral ingestion.

17Ospolot (Sulthiame) Tablets
CategoryNeurology oral anticonvulsant
Description

Anticonvulsant tablets indicated for behavioural disorders associated with epilepsy, hyperkinetic behaviour, temporal lobe epilepsy, and myoclonic seizures.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

New subsidiary pharma company established by Phebra Group to help fulfill medicine shortages in the Australian health system. Core focus is addressing medicines shortages and other pharmaceutical needs via sourcing alternative products in the global market and in-licensing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Collaborative drug development partnership for leukemias and pancreatic cancer research. Phebra and University of Wollongong working together on promising drug development for treatment of these cancers.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-03
Description

UK-based specialty hospital pharma company. Phebra Holdings completed a share purchase agreement with Flexipharm Austrading, strengthening collaboration and expanding Phebra's access to the UK market. Partnership involves a license and distribution agreement with several products already launched in the UK. Phebra has appointed Flexipharm as its exclusive distributor in the United Kingdom.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

Licensing agreement for development of oral arsenic trioxide formulation in the treatment of chronic Graft-Versus-Host and autoimmune diseases. Phebra announced new licensing agreement with Medsenic for this development.

5International Partner for Duchenne Muscular Dystrophy Treatment
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-05-01
Description

International distribution agreement for manufacture and supply of a new pharmaceutical for treatment of Duchenne Muscular Dystrophy.

phebra.com
Recent move16 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers6 records
1Biological E
TypeBroad incumbent
Description

South African-headquartered global specialty pharmaceutical company with significant sterile injectable manufacturing footprint. Comparable because both operate as vertically-integrated specialty injectable manufacturers serving hospital markets across multiple geographies, though Aspen operates at materially larger scale.

TypeDirect peer
Description

Global specialty generics pharmaceutical company with significant injectable portfolio serving hospital and specialty pharmacy channels. Comparable because both focus on specialty injectable products for hospital use across multiple international markets, with overlapping product categories in critical care and antidotes.

TypeDirect peer
Description

India-based specialty sterile injectable manufacturer focused on hospital critical care products with global distribution. Comparable because both operate specialty sterile injectable manufacturing businesses targeting hospital critical care customers in regulated international markets, though Claris has broader geographic reach and larger product portfolio.

TypeDirect peer
Description

Australian specialty pharmaceutical company with branded and generic product portfolio including injectables and specialty therapeutics. Comparable because both are Australian-headquartered specialty pharma companies serving similar hospital and specialty channels, though Mayne has stronger US generic franchise.

TypeBroad incumbent
Description

Global specialty pharmaceutical company with major sterile injectable franchise serving US, European, and MENA hospital markets. Comparable because both focus on hospital-channel specialty injectable products including critical care medicines, though Hikma operates with significantly larger scale and broader therapeutic coverage.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phebra

Specialty Sterile Injectable Pharmaceuticalsphebra.com

Phebra is an Australian pharmaceutical manufacturer founded in 1993 that develops, manufactures, and supplies sterile injectable critical care medicines to hospitals and healthcare professionals, operating TGA-licensed and FDA-accredited facilities in Sydney with subsidiaries across the UK, Canada, New Zealand, and Singapore.

What Phebra does

Phebra is an Australian-owned pharmaceutical manufacturer founded in 1993 (originally as Pharmalab, renamed Phebra in 2007) that develops, manufactures, and supplies sterile injectable critical care medicines for hospitals and healthcare professionals. Its portfolio spans more than 60 medicines across therapeutic areas including antidotes (Acetadote, DigiFab), cardiovascular drugs (Rapiblyk, Brevibloc, Narcan), oncology products (Phenasen/Arsenic Trioxide), pain management (Caldolor, Laceraine, Morphine Oral Solution), emergency and obstetric medicines, and diagnostic agents. Manufacturing is conducted at a TGA-licensed, GMP-compliant, FDA-accredited multi-purpose sterile injectables plant at Lane Cove West, Sydney, equipped with a robotic aseptic syringe and vial line; the facility was expanded in 2019 ($4M, +3,000m²) and again in 2020, with further capacity investment committed through 2026. Manufacturing licenses have been progressively broadened, in 2022 to include clinical trials therapeutic goods and in 2025 to include prescription oral and dermatological solutions.

The business operates through three revenue streams: direct product sales via the PhebWeb online ordering system and Therapeutic Specialist Representatives in Australia; licensing and distribution agreements with international partners (e.g., Flexipharm Austrading for the UK, Healthcare Logistics for NZ); and contract development and manufacturing services for other pharmaceutical companies. Customer segments are hospitals and healthcare professionals (primary), plus pharmaceutical companies seeking Asia-Pacific commercialization partners. Pricing is tiered across healthcare providers, licensed wholesalers, and credit accounts requiring minimum $10,000/quarter spend over three consecutive quarters. The group has established wholly-owned subsidiaries in the UK (2018), Canada (2019), New Zealand, and Singapore, holds a minority equity stake in Flexipharm Austrading (2021), and in 2024 launched subsidiary Phero Pharma to address Australian medicine shortages through in-licensing and alternative global sourcing.

Phebra's strategic posture is anchored in regulatory moats (TGA, FDA, GMP), a niche critical-medicines portfolio where supply security matters to hospitals, and incremental geographic and dosage-form expansion. Recent moves include pipeline expansion (Rapiblyk in March 2026, Anaesthetic Wound Gel in April 2026, Sterile Theatre Packs in 2023), a co-development partnership with the University of Wollongong for leukemia and pancreatic cancer drug development (2023), and a licensing deal with Medsenic for oral arsenic trioxide (2021). The company remains privately held with no disclosed funding rounds or revenue figures, and headcount is described as 'more than 130 people' against a stated 51-100 band.

Phebra firmographics

Firmographics
Name
Phebra
Legal name
Phebra Pty Ltd
Website
https://phebra.com
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
51–100 employees
Short description
Phebra is an Australian pharmaceutical manufacturer founded in 1993 that develops, manufactures, and supplies sterile injectable critical care medicines to hospitals and healthcare professionals, operating TGA-licensed and FDA-accredited facilities in Sydney with subsidiaries across the UK, Canada, New Zealand, and Singapore.
Ownership category
akta.pro rank

Phebra industry classification

Industry
Product category
Specialty Sterile Injectable Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Sterile injectable pharmaceuticals
  • Critical care medicines
  • Pharmaceutical contract manufacturing
  • Specialty hospital pharmaceuticals
  • Clinical trial drug manufacturing

Where Phebra is headquartered

Location

Headquarters

HQ city
Lane Cove
HQ country
Australia
HQ region
Oceania

Offices6 records

Markets served

Phebra business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Direct sales of manufactured sterile injectable pharmaceuticals to healthcare providers, hospitals, and wholesalers through PhebWeb online ordering system and field sales representatives. Products sold include over 60 medicines across therapeutic areas.
  2. License and Distribution Agreements: License and distribution agreements with international partners such as Flexipharm Austrading for UK market access. Phebra out-licenses products globally across Pacific region, Asia, Europe, Canada, South Americas and Middle East.
  3. Contract Manufacturing: Contract development and manufacturing services for other pharmaceutical companies on a fee-for-service basis

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goHealthcare Provider Orders
Unit PricingPay-as-you-goLicensed Wholesaler Orders
SubscriptionMonthlyCredit Account Customers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels3 records

Phebra product offering

Product offering

Core offering

Phebra develops, manufactures, and supplies high-quality sterile injectable pharmaceuticals and critical medicines for serious and life-threatening conditions. Operating from a TGA-licensed, GMP-compliant and FDA-accredited facility in Lane Cove West, Sydney, it produces over 60 medicines across therapeutic categories including antidotes, cardiovascular, oncology, pain management, anaesthesia, neonatal care, and diagnostics, and is licensed to manufacture therapeutic goods for clinical trials. The company also provides contract development and manufacturing services and licenses its products globally through distribution partners.

Product overview

Phebra is an Australian pharmaceutical company that develops, manufactures, and supplies high-quality sterile injectable pharmaceuticals and critical medicines. The core product portfolio includes over 60 medicines across therapeutic areas: antidotes (Acetadote, DigiFab), cardiovascular drugs (Rapiblyk, Brevibloc, Narcan), oncology products (Phenasen/Arsenic Trioxide), pain management (Caldolor, Laceraine Gel, Morphine Oral Solution), emergency medicines, diagnostic agents (Charcotrace, Retinofluor), and infusion solutions. The company operates the PhebWeb online ordering system for customer direct ordering. In March 2024, Phebra established subsidiary Phero Pharma to address medicines shortages through alternative sourcing and in-licensing. Manufacturing is conducted at TGA-licensed facilities in Sydney, with distribution across Australia, New Zealand, Canada, UK, and Singapore.

Differentiator

Problem solved

Functional benefit

Brands

  • Phero Pharma: Subsidiary company established to help fulfill medicine shortages in the Australian health system via sourcing alternative products in the global market and in-licensing.

Products and services

  • Acetadote (Acetylcysteine) Concentrated Injection Concentrated injectable antidote for paracetamol (acetaminophen) overdose used to protect the liver against hepatotoxicity in hospital and emergency settings.
  • Phenasen (Arsenic Trioxide) Concentrated Solution for Infusion Concentrated solution for infusion used for the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), including marketing approval for IV arsenic trioxide in Canada via Phebra Canada Inc.
  • Rapiblyk (Landiolol Hydrochloride) Powder for Injection for Infusion Powder for injection for infusion providing rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter, and non-compensatory sinus tachycardia, supplied to Australian healthcare settings.
  • Narcan (Naloxone Hydrochloride) Injection Injectable opioid antagonist used for complete or partial reversal of opioid depression, including respiratory depression, in emergency and hospital settings.
  • DigiFab (Digoxin-Specific Antibody Fragment) Powder for Injection Powder for injection used for the treatment of life-threatening or potentially life-threatening digoxin toxicity or overdose in hospital settings.
  • Brevibloc (Esmolol Hydrochloride) Injection/Powder Short-acting beta-blocker injection/powder for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in hospital and perioperative settings.
  • Caldolor (Ibuprofen) Concentrated Solution for Injection Concentrated IV solution of ibuprofen for the management of acute postoperative pain and reduction of fever in adults requiring IV administration.
  • Laceraine Topical Wound Anaesthetic Gel Topical lidocaine/adrenaline/tetracaine wound anaesthetic gel for wound closure and cleaning of painful minor wounds, supplied to healthcare professionals and hospital settings.
  • Tadim (Colistimethate Sodium) Powder for Nebuliser Solution Powder for nebuliser solution indicated for treatment of lung colonisation and infections caused by Pseudomonas aeruginosa in cystic fibrosis patients.
  • Cafnea (Caffeine Citrate) Injection/Oral Solution Caffeine citrate injection and oral solution for the short-term treatment of apnoea of prematurity in infants in neonatal hospital settings.
  • Syntometrine (Ergometrine and Oxytocin) Injection Injection indicated for active management of the third stage of labour and the prevention and treatment of post-partum haemorrhage.
  • Sterile Theatre Packs Ready-to-use sterile theatre packs, including bupivacaine and lidocaine with adrenaline presentations, supplied for surgical anaesthesia and analgesia in hospital operating theatre settings.
  • Morphine Oral Solution Oral morphine solution for short-term management of severe pain when other treatment options have failed.
  • Aramine (Metaraminol) Solution for Injection Solution for injection for prevention and treatment of acute hypotensive states occurring with spinal anaesthesia, and as adjunctive treatment of hypotension.
  • Charcotrace (Activated Charcoal) Injection Activated charcoal injection used as a diagnostic agent for stereotactic localisation of impalpable breast lesions prior to surgical excision.
  • Carbosorb X (Activated Charcoal) Suspension Oral activated charcoal suspension indicated for treatment of poisoning and drug overdosage by oral ingestion.
  • Ospolot (Sulthiame) Tablets Anticonvulsant tablets indicated for behavioural disorders associated with epilepsy, hyperkinetic behaviour, temporal lobe epilepsy, and myoclonic seizures.

Quantifiable outcome

  • 328 tonnes carbon saved per year through energy efficiency initiatives
  • +1 more outcomes

Companies that use Phebra

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Phebra technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Phebra partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Phero PharmacoreStrategic or Co-development Partner · 1 March 2024New subsidiary pharma company established by Phebra Group to help fulfill medicine shortages in the Australian health system. Core focus is addressing medicines shortages and other pharmaceutical needs via sourcing alternative products in the global market and in-licensing.
  • University of WollongongcoreStrategic or Co-development Partner · 1 August 2023Collaborative drug development partnership for leukemias and pancreatic cancer research. Phebra and University of Wollongong working together on promising drug development for treatment of these cancers.
  • Flexipharm Austrading Ltd.coreChannel Partner/ Reseller/ Distributor · 3 November 2021UK-based specialty hospital pharma company. Phebra Holdings completed a share purchase agreement with Flexipharm Austrading, strengthening collaboration and expanding Phebra's access to the UK market. Partnership involves a license and distribution agreement with several products already launched in the UK. Phebra has appointed Flexipharm as its exclusive distributor in the United Kingdom.
  • MedseniccoreStrategic or Co-development Partner · 1 July 2021Licensing agreement for development of oral arsenic trioxide formulation in the treatment of chronic Graft-Versus-Host and autoimmune diseases. Phebra announced new licensing agreement with Medsenic for this development.
  • International Partner for Duchenne Muscular Dystrophy TreatmentminorStrategic or Co-development Partner · 1 May 2020International distribution agreement for manufacture and supply of a new pharmaceutical for treatment of Duchenne Muscular Dystrophy.

Scale indicators7 records

Recent moves16 records

Expansion highlights8 records

Phebra competitors and assessment

Company assessment

Peers

  • Biological E:

Broad incumbents

  • Aspen Pharmacare: South African-headquartered global specialty pharmaceutical company with significant sterile injectable manufacturing footprint. Comparable because both operate as vertically-integrated specialty injectable manufacturers serving hospital markets across multiple geographies, though Aspen operates at materially larger scale.
  • Hikma Pharmaceuticals: Global specialty pharmaceutical company with major sterile injectable franchise serving US, European, and MENA hospital markets. Comparable because both focus on hospital-channel specialty injectable products including critical care medicines, though Hikma operates with significantly larger scale and broader therapeutic coverage.

Direct peers

  • Alvogen: Global specialty generics pharmaceutical company with significant injectable portfolio serving hospital and specialty pharmacy channels. Comparable because both focus on specialty injectable products for hospital use across multiple international markets, with overlapping product categories in critical care and antidotes.
  • Claris Lifesciences: India-based specialty sterile injectable manufacturer focused on hospital critical care products with global distribution. Comparable because both operate specialty sterile injectable manufacturing businesses targeting hospital critical care customers in regulated international markets, though Claris has broader geographic reach and larger product portfolio.
  • Mayne Pharma: Australian specialty pharmaceutical company with branded and generic product portfolio including injectables and specialty therapeutics. Comparable because both are Australian-headquartered specialty pharma companies serving similar hospital and specialty channels, though Mayne has stronger US generic franchise.

Market position

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Phebra social profiles

Digital presence

Phebra compliance and trust

Trust signal

Compliance6 records

Phebra financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phebra leadership team

Management profile

Number of profiles

Profiles2 records

Phebra subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Phebra funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phebra M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phebra

What does Phebra do?

Phebra develops, manufactures, and supplies high-quality sterile injectable pharmaceuticals and critical medicines for serious and life-threatening conditions. Operating from a TGA-licensed, GMP-compliant and FDA-accredited facility in Lane Cove West, Sydney, it produces over 60 medicines across therapeutic categories including antidotes, cardiovascular, oncology, pain management, anaesthesia, neonatal care, and diagnostics, and is licensed to manufacture therapeutic goods for clinical trials. The company also provides contract development and manufacturing services and licenses its products globally through distribution partners.

Is Phebra a public or private company?

Phebra is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Phebra founded?

Phebra was founded in 1993. It employs 51 to 100 people.

Where is Phebra based?

Phebra is headquartered in Lane Cove, Australia, in the Oceania region.

How does Phebra make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are license and Distribution Agreements and contract Manufacturing.

Who are Phebra's main competitors?

Biological E is listed as a peer. Broad incumbents are Aspen Pharmacare and Hikma Pharmaceuticals. Direct peers are Alvogen, Claris Lifesciences and Mayne Pharma.

Does Phebra have an API?

No public API is recorded for Phebra.

What industry is Phebra in?

Phebra's product category is Specialty Sterile Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMedsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.Medsenic, BioSenic's subsidiary, signed global licensing, supply, and commercialization agreements with Phebra Pty Ltd. for oral arsenic trioxide (OATO) for chronic graft-versus-host disease. The updated terms aim to attract investors for the upcoming Phase 3 trial and simplify sublicensing.PR NewswirePhebra Acquires Equity Stake in UK Specialty Hospital Pharma Company Flexipharm AustradingAustralian pharmaceutical group Phebra Holdings has completed a share purchase agreement to acquire an equity stake in UK specialty hospital pharmaceutical company Flexipharm Austrading Limited. This strategic investment deepens the existing collaboration between the two entities, leveraging Flexipharm's infrastructure to advance market access for critical care products in the UK and potentially wider European markets.PR NewswirePhebra Acquires Equity Stake In UK Specialty Hospital Pharma Company Flexipharm AustradingPhebra completed a share purchase of UK hospital specialty pharma company Flexipharm Austrading, building on its existing distribution agreement for critical care medicines. The investment strengthens Phebra's UK and European market access and deepens its collaboration with founder Michael Clark.PR NewswireFinal Results of Bioavailability Study of Phebra's Oral Arsenic Capsule for Acute Promyelocytic Leukaemia (APL) Confirm Bioequivalence of Oral and IV FormulationsPhebra confirmed the bioequivalence of its oral arsenic trioxide capsules to intravenous formulations through final results from the ALLG APML5 bioavailability study. The trial, conducted across Australian hospitals with 31 patients, demonstrated that the oral formulation offers a viable treatment option for Acute Promyelocytic Leukaemia. This development highlights Phebra's potential to provide a more convenient therapy that reduces hospital infusion time for patients.PR NewswireFlexipharm Austrading Announces Product Update on Arsenic Trioxide PhebraFlexipharm Austrading announced an MHRA-approved update to the storage stability specifications for its arsenic trioxide injection product, Arsenic Trioxide Phebra, extending in-use stability time from 24 to 48 hours at room temperature and from 48 to 72 hours under refrigeration. The vial presentation, the first of its kind for arsenic trioxide in the UK, reduces sharps injury risks compared to traditional glass ampoules and eliminates the need for filter needles or straws during preparation. The product is manufactured by Australian partner Phebra Pty Ltd and distributed exclusively by Flexipharm in the UK.PR NewswireFlexipharm Austrading Announces Launch of Arsenic Trioxide Phebra (Arsenic Trioxide 1mg/ml Concentrate for Solution for Infusion)Flexipharm Austrading announced the commercial launch of Arsenic Trioxide Phebra in the UK following MHRA Marketing Authorisation approval, making it the first generic arsenic trioxide injection product available in the country. The product, supplied by Australian partner Phebra Pty Ltd, uses a safer glass vial presentation that reduces sharps injury risks and is priced 7.7% lower than traditional ampoules at £2,700 per pack of 10 x 10ml vials. The company, founded in 2018, aims to address supply security and presentation concerns for critical hospital medicines used by the NHS.